key: cord-0687612-maxsgou8
authors: Mohamed, Kawthar; Yazdanpanah, Niloufar; Saghazadeh, Amene; Rezaei, Nima
title: Computational Drug Discovery and Repurposing for the Treatment of COVID-19: A Systematic Review
date: 2020-11-19
journal: Bioorg Chem
DOI: 10.1016/j.bioorg.2020.104490
sha: 9fa39b960f0bd99858fc91dfb9bdb269295f506a
doc_id: 687612
cord_uid: maxsgou8

Background Since the beginning of the novel coronavirus (SARS-CoV-2) disease outbreak, there has been an increasing interest in finding a potential therapeutic agent for the disease. Considering the matter of time, the computational methods of drug repurposing offer the best chance of selecting one drug from a list of approved drugs for the life-threatening condition of COVID-19. The present systematic review aims to provide an overview of studies that have used computational methods for drug repurposing in COVID-19. Methods We undertook a systematic search in five databases and included original articles in English that applied computational methods for drug repurposing in COVID-19. Results Twenty-one original articles utilizing computational drug methods for COVID-19 drug repurposing were included in the systematic review. Regarding the quality of eligible studies, high-quality items including the use of two or more approved drug databases, analysis of molecular dynamic simulation, multi-target assessment, the use of crystal structure for the generation of the target sequence, and the use of AutoDock Vina combined with other docking tools occurred in about 52%, 38%, 24%, 48%, and 19% of included studies. Studies included repurposed drugs mainly against non-structural proteins of SARS-CoV2: the main 3C-like protease (Lopinavir, Ritonavir, Indinavir, Atazanavir, Nelfinavir, and Clocortolone), RNA-dependent RNA polymerase (Remdesivir and Ribavirin), and the papain-like protease (Mycophenolic acid, Telaprevir, Boceprevir, Grazoprevir, Darunavir, Chloroquine, and Formoterol). The review revealed the best-documented multi-target drugs repurposed by computational methods for COVID-19 therapy as follows: antiviral drugs commonly used to treat AIDS/HIV (Atazanavir, Efavirenz, and Dolutegravir Ritonavir, Raltegravir, and Darunavir, Lopinavir, Saquinavir, Nelfinavir, and Indinavir), HCV (Grazoprevir, Lomibuvir, Asunaprevir, Ribavirin, and Simeprevir), HBV (Entecavir), HSV (Penciclovir), CMV (Ganciclovir), and Ebola (Remdesivir), anticoagulant drug (Dabigatran), and an antifungal drug (Itraconazole). Conclusions The present systematic review provides a list of existing drugs that have the potential to influence SARS-CoV2 through different mechanisms of action. For the majority of these drugs, direct clinical evidence on their efficacy for the treatment of COVID-19 is lacking. Future clinical studies examining these drugs might come to conclude, which can be more useful to inhibit COVID-19 progression.

The 21 st century has allowed for coronaviruses to become well perfected and higher pathogenic to humans. In 2003 the world experienced severe acute respiratory syndrome of coronavirus (SARS-CoV) outbreak. It started from China and spread to five continents, with the calculated fatality rate of 9.6% during the outbreak period (1) . In 2012, the second outbreak of the Middle East respiratory syndrome-related coronavirus (MERS-CoV) occurred in the Arabian Peninsula, with the fatality rate of about 34.4% (2) . An outbreak of the novel coronavirus disease has emerged in Wuhan, Hubei Province, China, in December 2019. It is expanding at a remarkable pace so that on March 11 th , 2020, the World Health Organization (WHO) declared COVID-19 as a pandemic (3) . As of writing this, there are more than one million people infected with, and more than 80,000 people died from COVID-19.

Having multiple routes of transmission and lack of full adherence to social distancing guidelines are important barriers making its prevention difficult (4) (5) (6) (7) . Also, despite widespread efforts, finding the origin, diagnosis, treatment, and management of has been a challenge for the health care system (8) (9) (10) (11) . Such efforts have so far occurred separately in different biomedical disciplines, particularly immunology, genetics, medical biotechnology, molecular engineering, nutrition, picotechnology, and regenerative medicine , highlighting the need for an integrated view of COVID-19 (33-35) aimed at doing science of high-quality (36). With respect to the absence of specific treatment for COVID -19, we can provide only the combination of symptomatic treatment and supportive measures (37, 38), that for a significant proportion of cases, will not suffice. The fact is given as the disease can cause hyper inflammation affecting multiple systems and organs making it difficult to treat (26, 39-45).

The process of de novo drug design is hugely time-consuming. Drug repurposing, also known as drug repositioning or drug re-profiling, works as an alternate, systematic method in drug discovery that can aid in determining the new indications for the existing drugs. It is of high importance that this method repurposes drugs which their safety and pharmacokinetics have been recognized so far. Hence, it would confidently reduce the risk of adverse side effects, drug interactions, and drug development time and expenditure. The fastness of the computational or in silico techniques has made them an exciting approach to the drug repurposing world (46) . There are two main approaches to the computational drug repurposing process: target-based and disease-based (47) . The former allows the drug and the target to interact with each other leading to the establishment of drug-target interactions.

The latter utilizes datasets to determine new indications for already approved drugs from comparisons of characteristics of diseases. Computational drug repurposing approaches differ from each other in some points, such as target modeling, algorithms, and the drug bank or data sets (48) .

Since the beginning of the COVID-19 outbreak, there has been an increasing interest in finding a potential therapeutic agent for COVID-19. Considering the matter of time that this pandemic is not the time of trial and error (49) and also the possibility of re-infection (50) , the computational methods of drug repurposing offer the best chance of selecting one drug from a list of approved drugs for the life-threatening condition of COVID-19. The present systematic review aims to provide an overview of studies that have used computational methods for COVID-19 drug repurposing.

We prepared this review according to the Preferred Reporting Items for Systematic reviews and Meta-analyses (PRISMA) statement (51) . Before beginning the database search, the protocol of the present systematic review was developed and submitted to PROSPERO.

We undertook a systematic search in five databases, including PubMed, Scopus, Google Scholar, Cochrane, and the WHO global health library. The search terms and keywords included but not limited to the following terms for the disease; "Novel coronavirus", "2019 nCoV", "COVID-19", "Wuhan coronavirus", "Wuhan pneumonia", "SARS-CoV-2", and for the drug repurposing; "Antiviral Agents", "Drug Therapy", "therapeutic use", "therapeutic agents", "Drug Repositioning", "virtual screening", "docking", and "computational". We imported search results into EndNote Version X9, Clarivate Analytics, USA.

The present systematic review included original articles in English that applied computational methods for COVID-19drug repurposing. Eligible studies should repurpose drugs that are already approved by at least one of the following authorities: the European Medicines Agency (EMA), the Japan Pharmaceuticals and Medical Devices Agency (PMDA), or the U.S. Food and Drug Administration (FDA). Studies that either investigated biologic agents (such as interleukins, vaccines, and miRNA), nutritional supplements, and traditional medicines or focused on protein structure prediction or determination rather than having a drug discovery project were not eligible to be included in this review. Also, studies examining a wet lab approach were excluded. By considering the above criteria, two authors (K.M. and N.Y.) independently performed title/abstract screening and detailed review. In the case of disagreement, the two authors discussed the reasons to reach a consensus. When they were unable to reach a consensus, the third author (A.S.) was consulted.

The first two reviewers (K.M. and N.Y.) extracted the following data from each included publication: the first author, year of publication, country of origin, drug repurposing method, sequence alignment, target preparation, the resource for approved drugs, the visualization tool, molecular docking tool, coronavirus strain, target structures, candidate therapeutic agents, and the authors' conclusions. A consensus discussion between the two authors was made on items of discrepancies. The third author (A.S.) was involved in the points on which consensus did not happen.

The idea of bias in computational drug research studies is not well established. However, few statements can aid in assessing bias systematically. Cleves et al. [4] argue about a bias that is produced by two dimensional (2D) descriptors in compound screening. The use of the method would reduce the probability of finding novel compounds. Also, Hert et al. [5] have introduced a bias that occurs when screening drug libraries, and therefore the result of screening would be restricted to the compounds with known biological effects. It is a threat to novelty, and a possible solution to this bias is the development of useful decoys (DUD), which use a standard set of ligands to make comparisons of different docking methods simultaneously [6] .

Recently, Scannell et al. [7] have presented a bias that occurs when targeting a single molecule with a single compound and can be avoided with a multi-target approach. Eventually, it is crucial to point out the molecular flexibility of the targets. This point is usually missed out when one docking method is applied. The best way of putting this bias into account is to use the molecular dynamics simulations, a robust method with many functions that can predict the drug-target interaction in a better way. The most crucial function of molecular dynamics simulations is to provide multiple receptor conformations, in addition to many other sophisticated analyses that can accurately differentiate between a proper docking and an inadequate docking (52) .

According to the potential issues of bias, a tool was designed for the assessment of five main aspects of quality of studies included in the present systematic review: design (mono-target vs. multi-target), target template modeling (crystal structure, homology modeling, and cocrystal ligand), docking tools, molecular dynamics simulation (yes vs. no), and the resource for approved drugs. The quality of each eligible article was independently appraised by two authors (K.M. and N.Y.) and then was double-checked by the third author (A.S.).

There were 3256 studies retrieved from the database search, of which 2171 papers remained after the removal of duplicates ( Figure 1 ). We conducted title and abstract screening on these 2171 studies and nominated 93 of them for detailed review. Considering the inclusion and exclusion criteria, we excluded 72 studies for different reasons as follows. There were studies not regarded as original research (n=18) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) (70) , studies proposed a novel drug, an unapproved drug, or no drug at all (n=9) (71) (72) (73) (74) (75) (76) (77) (78) (79) , studies reporting drugs against targets other than the novel coronavirus (also known as 2019-nCoV or SARS-CoV2) (n=10) (80) (81) (82) (83) (84) (85) (86) (87) (88) (89) , studies applying any methods other than computational methods for drug repurposing (n=33) , studies not published in full-text articles (n=1) (123) , and one study using network-based approach (124) . Finally, we included 21 original articles utilizing computational drug methods for COVID-19 drug repurposing .

As summarized in Table 1 (125, 127-130, 133-139, 141-145) , RNA dependent RNA polymerase (RdRp) (127, 128, 131, 144) , papain-like protease (PLP) (126, 132, 137, 144) , helicase (127, 144) , 3'-to-5' exonuclease (127), 2'-O-ribose methyltransferase (127, 135) , endoRNAse (127) , and spike (S) protein (140, 144) . There was only one study combined with in vitro experiments (134) . Table 2 represents the details of the appraisal of study quality. Regarding the number of approved drug databases, more than 50% of studies used two or more databases. About 38% of the studies analyzed the molecular dynamics simulations. For the item target, more than 70% of studies investigated only one viral structure as the target. Also, more than 50% of the studies used homology modeling for the generation of the target sequence. AutoDock Vina was the only docking tool in more than 80% of studies. Figure 2 displays the percentages of studies reporting high-quality items.

Conserved structures in the viral genome represent a high potential to be target candidates.

While the phylogenetic tree inevitably undergoes evolutionary changes, a highly conserved structure can maintain its sequence among strains. Targeting such a highly conserved site will provide cross-reactive protection in different strains. Highly conserved elements of the 2019-nCoV (SARS-CoV2) include non-structural proteins such as 3CLP, RdRp, and PLP, and structural proteins, such as the S protein (78, 124) . Below is a target-based synthesis of data for COVID-19 drug repurposing as summarized in Table 4 .

The main protease of the 2019-nCoV, also known as 3CLP or the C30 endopeptidase, is a highly conserved element that shares 96.1% similarity with the main protease of SARS-CoV.

This protease is a member of the coronavirus polyproteins. When translation takes place, it is the first one that is auto-cleaved from the polyprotein. Then, it, in turn, would mediate the cleavage of the other 11 non-structural proteins that are vital for viral replication and transcription. Thus, 3CLP might serve as a marvelous target for COVID-19 therapy (78) .

Lopinavir and Ritonavir are the most documented candidate drugs that target 3CLP (Table 3) .

However, Wu et al. claimed that Lopinavir and Ritonavir have not an excellent binding score in docking compared to other drugs (144) . Moreover, Contini et al. developed molecular dynamics simulations, which are known to be more potent than docking in the prediction of the drug-target binding (147) . The authors showed that Ritonavir failed to form the interaction with the 3CLP (130) . The good binding energy and docking score for each one of Elbasvir, Simeprevir, Indinavir, and Atanzavir might nominate these drugs as candidates for the inhibition of 3CLP of SARS-CoV2. Interestingly, both Indinavir and Remdesivir might be effective against SARS-CoV2 infection due to their excellent docking scores and limited toxicity, as confirmed by Chang et al. (128) . Nelfinavir was also mentioned as one of the best drugs binding to the 3CLP. However, it appeared less efficient than Tegobuvir and Bictegravir when the affinity and the physical-chemical analysis parameters were calculated using SeeSAR (136, 145) . Nguyen et al. suggested an unusual inhibitor of 3CLP, Clocortolone, a medium-strength steroid that is used for dermatitis and has good binding scores making it a promising cleanser against SARS-CoV2 contaminated surfaces (139) .

Viral RdRp is an enzyme that accelerates the replication of RNA from a template RNA and shares around 97.08% of its sequence with SARS-CoV (131).

Among the drugs that target this protein, Remdesivir is a bold one which, by a triphosphate nucleotide, would act as an ATP-competitive inhibitor of RdRp and intervene with the viral RNA synthesis. Also, Remdesivir can bind to the human TMPRSS2, a protein that mediates the cleavage of the viral S protein and promotes the entry of SARS-CoV2 into the host cells (144) .

Ribavirin is another drug reported in two studies to interact with RdRp. It appeared not to be a very effective drug compared to other drugs (128, 131) .

PLP plays a crucial part in the initiation of infection through its ability to antagonize interferon (IFN) activity and deubiquitinate viral and cellular proteins (148) . 

Multi-target therapeutic (Table 3) agents are more useful than mono-target drugs ( Table 5) in terms of better predictive pharmacokinetics, better patient compliance, and reduced risk of drug interactions (149) . Simultaneously impacting different targets is, in particular, advantageous to approach individuals that express intrinsic or induced variability in drug response due to modifications in key disease-relevant biological pathways and activation of compensatory mechanisms (150, 151) . Below is a discussion of drugs repurposed for COVID-19 that target multiple viral elements.

This review revealed Atazanavir, Efavirenz, and Dolutegravir as the top-ranked drugs as arranged by the number of drugs. These drugs can similarly hit 3CLP, RdRp, helicase, 3'-to-5' exonuclease, 2'-O-ribose methyltransferase, and endoRNAse proteins (127, 135) . It is worth mentioning that this category contains the highest number of repetitions among the multi-target drugs repurposed for COVID-19 therapy. Initially, each one of Entecavir, Penciclovir, and Ganciclovir similarly hit RdRp, helicase, and 3'-to-5' exonuclease proteins.

Danoprevir has the same targets as the drugs mentioned above, with an exception to helicase, which is replaced by endoRNAse. Moreover, Dabigatran, Itraconazole, and Saquinavir hit RdRp, helicase, and spike proteins; however, the later one hits 3CLP instead of the spike protein. Furthermore, Sempremivir and Nelfinavir commonly hit 3CLP and helicase, and distinctively hit each one of the 3'-to-5' exonuclease and endoRNAse, respectively.

Indinavir and Remdesivir are the most documented drugs among dual-target drugs. These two drugs similarly target the 3CLP and desperately target each one of the helicase and RdRp, respectively. Also, Ribavirin is a drug with a dual effect; it targets RdRp and PLVP. Chloroquine is another doubtful drug. Three studies have suggested that this drug might inhibit the PLP and the E-channel (126, 133, 144) . In all of these studies, the binding energy of Chloroquine is acceptable, but it lacks an excellent value and as declared by Wu and colleagues who emphasize on not considering the drugs that do not have a specific target like Chloroquine (144). (21.52) . Also, the C trough /EC 50 ratio higher than one, which indicates that the compound can reach a trough serum concentration of higher than 50% effective concentration, occurred in only three of nine drugs Nelfinavir, Lopinavir, and Tipranavir. Overall, Nelfinavir seems to be the best among different anti-protease inhibitors, with both the lowest EC 50 and the highest SI as well as the C trough /EC 50 ratio higher than one.

Because of the absence of any effect of Darunavir on SARS-CoV cultured in Caco-2 cells, there is no SI attached to Darunavir (155) . By contrast, Remdesivir could reduce the cytopathogenic effect (CPE) of SARS-CoV at low doses (EC 50 = 0.11 μM) and represent a noticeable SI higher than 900.

The study (156) assembly. However, hydroxychloroquine has become more important for fewer adverse effects and drug-drug interactions. In vitro investigation points out a lower 50% effective concentration required for Chloroquine compared to hydroxychloroquine to exert anti-SARS-COv2 effects in Vero cells (157) . It would indicate the more potency of Chloroquine than its analog, hydroxychloroquine, in inhibiting SARS-CoV2 replication.

In conclusion, at this growing rate of COVID-19 pandemic and increasing mortality rate, it seems quite unachievable to design a novel specific drug for it. Therefore, it puts a spotlight on the drug repurposing system, and if we consider the matter of time, computational methods are our best shots. Since the incidence of this outbreak, many investigations have been conducted to present an appropriate therapeutic agent for COVID-19 utilizing computation drug repurposing approaches. Therefore, the review intended to cover all these studies to help build a concise framework for future research into COVID-19 therapy.

All methods have inherent limitations, and computational methods are not exceptional in this field. Thus, the use of models -which are illustrations of the real world-in running computational research, might be an inherent limitation. Besides, the results reported by docking score, binding energy, binding affinity, and other numerical variants were immensely divergent across twenty-one studies included in the review. Having the fact in mind that there is not any specific tool for quality assessment and comparison of computational repurposing methods; it would not be possible to evaluate the potential candidates from different studies to declare which is more significant.

Despite its limitations, the present systematic review provides a list of existing drugs that have the potential to influence SARS-CoV2 through different mechanisms of action. And in the near future, clinical studies examining these drugs might come to conclude, which can be more useful to inhibit COVID-19 progression.

The authors declare that they have no competing interests

There is no funding for the present study Table 1 Characteristics of studies included in the systematic review Table 2 Quality of studies included in the systematic review Table 3 Multi-target drugs repurposed for COVID-19 Table 4 The main findings of studies included in the systematic review Table 5 Mono-target drugs repurposed for COVID-19 Table 4 The main findings of studies included in the systematic review

Sekhar 2020 -By performing virtual high throughput screening in the superDRUG2 database, Saquinavir and Beclabuvir turned out as best probable candidates or the treatment of COVID-19.

Elfiky 2020

-IDX-184, Sofosbuvir, and Ribavirin can bind to COVID-19 RdRP with high affinity and change the viral protein function, which leads to its elimination. Among the mentioned drugs, better results were observed about IDX-184 and then about Sofosbuvir in inhibition of novel coronavirus 2019.

Alamri 2020 -Three top 3CLpro inhibitor candidates in this study were compound 621, Paritaprevir, and Simeprevir, which are potent inhibitors in low micromolar concentrations.

Chang 2020 -Indinavir and Remdesivir were identified as potential therapeutic agents, as they possess docking sites that have a significant overlap with the protein pockets. Due to their limited toxicity, they can be used in COVID-19 treatment.

Arya 2020

-Chloroquine was selected as a potential inhibitor of viral PLpro. This drug works against the viral infection in both entry-level and post-entry stages. The latter might be due to the inhibition of the main viral protein.

-Formoterol, a drug that mainly works as a bronchodilator, and it might be used to improve breathing, plus having an inhibitory effect on the viral PLpro.

Beck 2020

-Through the DTI model, the viral proteinase-targeting drugs were predicted to act better on the viral replication process than viral proteinase. -An antiviral drug, such as guanosine analogs (e.g., acyclovir, ganciclovir, and penciclovir), reverse transcriptase inhibitors, and integrase inhibitors, were more than proteinase inhibitors in the results. Chen 2020

-Dual-component HCV drugs, Epclusa (velpatasvir/sofosbuvir), and Harvoni (ledipasvir/sofosbuvir) act on two viral proteins, thus reducing the viral resistance ability. In addition to their easy administration (orally) with minimal side effects. -Diosmin and hesperidin, which are flavonoid glycosides from citrus fruits, fit amazingly into the substrate-binding site and block it. However, these chemotherapy drugs have many adverse effects and should be administered intravenously. -Venetoclax, which is also a chemotherapy drug, is loaded with side effects, including upper respiratory tract infection.

-Indinavir was selected by both COVID-19 main protease (PDB code 6LU7) and COVID-19 3CL-PRO proteinase.

-Lopinavir and Atazanavir were best selected for 3CL-PRO -Cobicistat was chosen as a potential COVID-19 primary protease inhibitor.

-Angiotensin II and GHRP-2 were selected too. Although these might bind the target, they are cleaved by the target too because these are peptides, and they are just served as substrates. -Caspofungin identification is unexpected and doubtful.

-Further parameterization schemes and calculations are required to confirm these compounds' effectiveness.

-Although both the anti-SARS PLpro (GRL-0667, GRL-0617, and Mycophenolic acid) and the anti-HCV NS3 (Telaprevir, Boceprevir, and Grazoprevir) binding energies for 2019-CoV PLpro are a bit less than that calculated for SARS PLpro and HCV, they can still bind to the active site (C112, H273, and D287) of 2019-nCoV PLpr.

Hosseini 2020 -The FDA approved anti HCV NS3/4A protease, Simeprevir, demonstrated better affinity than Lopinavir and Ritonavir, in binding with COVID-19 main protease.

Jin 2020

-The virtual screening revealed that cinanserin is a well-known serotonin antagonist that fits firmly into the substrate-binding pocket, with having an IC50 value of 124.93 μM for Mpro. -High-throughput screening results -Ebselen, a drug that is currently in the clinical trial, has the most robust inhibition of Mpro activity with an IC50 of 0.48 μM.

-Four drugs were found that act as potential inhibitors against 2019nCoV; they are as follow:

Raltegravir and Paritaprevir are against 3CLpro Bictegravir and Dolutegravir are against 2'-OMTase

Li 2020

-All of the following molecules, Prulifloxacin, Bictegravir, Nelfinavir, and Tegobuvir, showed stable binding conformations with the main viral protease. -Affinity and physical-chemical properties analysis using SeeSAR suggests that Prulifloxacin, Tegobuvir, and Bictegravir are better than Nelfinavir.

Lin 2020

-Due to the unknown catalytic mechanisms of CEP_C30 and PLVP domains, we cannot accurately define whether ritonavir, Lopinavir, and darunavir are competitive or non-competitive inhibitors. However, it can be predicted that both ritonavir and Lopinavir have an inhibitory effect on CEP_C30, and acclaim that ritonavir has a better effect. -In addition to the ability of darunavir to bind PLVP by changing its conformation with little conformation changes and that might make it a competitive inhibitor.

Nguyen 2020

-Three top suggested drugs are: Bortezomib, Flurazepam, and Ponatinib.

-The seventh suggested drug is Clocortolone, a topical medium-strength steroid that is used for dermatitis. Hence, Clocortolone can be applied as a cleanser for 2019-nCoV contaminated surfaces or materials.

Nguyen 2020 -Fifteen anti-2019-nCoV molecules were detected in this study, which is observed to have more druggable features than FDA approved HIV inhibitors such as Kaletra (or Aluvia) and Norvir.

Smith 2020

-Nitrofurantoin, Isoniazid pyruvate, Eriodictyol, and Pemirolast are the four top candidates in which the first three were observed to have more affinity for the ACE2 receptor part of the ACE2 receptor-spike protein interface. Therefore, it is expected that these affinities and interactions may restrict the binding of nCoV-2019 spike protein with the ACE2 receptor and hence, inhibit the spread of infection.

Ton 2020

-The top predicted inhibitors share a number of characteristics with two known protease inhibitors (aka Lopinavir and compound 80), which are also likely to bind to the SARS-COV-2 Mpro. -Compound 80" is a non-peptide small molecule inhibitor of SARS Mpro, with a reported IC50 of 0.95 μM.

-ZINC000541677852 was selected as the top identified molecule that has a better binding effect than both Lopinavir and compound 80.

Wang 2020 -Carfilzomib, Eravacycline, Valrubicin, Lopinavir, and Elbasvir, have inhibitory activities against COVID-19 protease.

-Streptomycin, a charged molecule, might be an inhibitor of COVID-19 protease.

Wu 2020

-Virtual screening introduced many compounds able to bind the ACE2 target. However, none of these drugs bind with the contact surface of the ACE2-Spike complex. Thus, these compounds could merely inhibit ACE2 enzyme activities rather than the inhibition of the viral infections caused by ACE2. -2-PROTAC technology might be the right choice for the proteins that finding their inhibitor is quite hard. In this technology, the proteins are first degraded, then this leads the inhibition if the viral infection, e.g., natural hesperidin was selected for Spike protein.

In this condition, the viral infection process could be inhibited by any small molecule that interferes with the re-folding of the spike when it is bound to it. -The drugs that do not have clear targets are not suggested, such as:

Chloroquine phosphate, which might target Nsp3b and E-channel. Ritonavir's possible target is Nsp3c or E-channel. -Lopinavir's possible target is Nsp3b, Nsp3c, helicase, NRBD, or E-channel.

-For both Lopinavir and Ritonavir, no evident bonding to the main proteases (aka 3CLpro, PLpro, RdRp) was seen.

-4-The triphosphate nucleotide product of Remdesivir, Remdesivir-TP has two effects:

It is a competitive substrate ATP with RdRp. Hence it intervenes with viral RNA synthesis. It has good binding, a score of -112.8. It was predictive to bind the human TMPRSS2, a protein that boosts the virus infection.

Xu 2020

-After two steps of docking performed, energy calculation was done on four final candidates, and these calculations voted for Nelfinavir as a potential inhibitor of COVID-19 main protease. -Pitavastatin, Perampanel, and Praziquantel were identified as potential Mpro inhibitors with moderate activities. The percentages of high-quality items Figure 2 The percentage of studies reported high-quality items

The distribution of multi-target drugs for COVID-19

Severe Acute Respiratory Syndrome (SARS)

Worldwide reduction in MERS cases and deaths since

COVID-19: Developing from an Outbreak to A Pandemic. Archives of medical research

COVID-19: Transmission, prevention, and potential therapeutic opportunities

Country Quarantine during COVID-19: Critical or Not? Disaster medicine and public health preparedness

COVID-19 affects healthy pediatricians more than pediatric patients

COVID-19: A Chimera of Two Pandemics. Disaster medicine and public health preparedness

Challenges for management of immune thrombocytopenia during COVID-19 pandemic

COVID-19 and telemedicine: Immediate action required for maintaining healthcare providers well-being

Microfluidic devices for detection of RNA viruses

International Efforts to Save Healthcare Personnel during COVID-19

COVID-19 in a Child with Primary Specific Antibody Deficiency

Cytokines and COVID-19: friends or foes?

Death due to COVID-19 in an Infant with Combined Immunodeficiencies. Endocrine, metabolic & immune disorders drug targets

Efficacy of Plasmapheresis and Immunoglobulin Replacement Therapy (IVIG) on Patients with COVID-19

The immune system and COVID-19: Friend or foe? Life sciences

The immune system as a target for therapy of SARS-CoV-2: A systematic review of the current immunotherapies for COVID-19

Immune-epidemiological parameters of the novel coronavirus -a perspective

Immunotherapy for SARS-CoV-2: potential opportunities

Interleukin-6 and severe COVID-19: a systematic review and meta-analysis

SARS-CoV-2-A Tough Opponent for the Immune System. Archives of medical research

Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies

COVID-19 and Medical Biotechnology

Recent advances in drug repositioning for the discovery of new anticancer drugs

Computational methods for drug repurposing

Drug repurposing: progress, challenges and recommendations

COVID-19 pandemic is not the time of trial and error. The American journal of emergency medicine

With Risk of Reinfection, Is COVID-19 Here to Stay? Disaster medicine and public health preparedness

Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P)

An Overview of Molecular Modeling for Drug Discovery with Specific Illustrative Examples of Applications

Artificial intelligence finds drugs that could fight the new coronavirus

The Author's Response: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

Baricitinib as potential treatment for 2019-nCoV acute respiratory disease

Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR

Clinical research progress of antiviral drugs for the novel coronavirus pneumonia

COVID-19: combining antiviral and anti-inflammatory treatments. The Lancet Infectious Diseases

Daily briefing: The potential for repurposing existing drugs to fight COVID-19 coronavirus

Dose prediction of lopinavir/ritonavir for 2019-novel coronavirus (2019-nCoV) infection based on mathematic modeling

Drug trials under way

Letter to the Editor: Case of the Index Patient Who Caused Tertiary Transmission of Coronavirus Disease 2019 in Korea: the Application of Lopinavir/Ritonavir for the Treatment of COVID-19 Pneumonia Monitored by Quantitative RT-PCR

Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases

The possibility of using

LPV/r) as treatment for novel coronavirus (2019-nCov)pneumonia: a quick systematic review based on earlier coronavirus clinical studies

Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines

Promising Inhibitor for 2019-nCoV in Drug Development

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

A Systematic Review of Lopinavir Therapy for SARS Coronavirus and MERS Coronavirus-A Possible Reference for Coronavirus Disease-19 Treatment Option

Thalidomide Combined with Low-dose Glucocorticoid in the Treatment of COVID-19 Pneumonia

Therapeutic options for the 2019 novel coronavirus (2019-nCoV)

Agile Discovery of Drugs and Natural Products for Emerging Epidemic 2019-ncov based on Computational Pharmacology

Alpha-ketoamides as broad-spectrum inhibitors of coronavirus and enterovirus replication Structure-based design, synthesis, and activity assessment

D3Targets-2019-nCoV: A Web Server to Identify Potential Targets for Antivirals Against 2019-nCoV

Drug and vaccine design against Novel Coronavirus (2019-nCoV) spike protein through Computational approach

Identification of critical determinants on ACE2 for SARS-CoV entry and development of a potent entry inhibitor

Silico Discovery of Novel Inhibitors Against Main Protease (Mpro) of SARS-CoV-2 Using Pharmacophore and Molecular Docking Based Virtual Screening from ZINC Database

Inhibition of the Main Protease 3CL-pro of the Coronavirus Disease 19 via Structure-Based Ligand Design and Molecular Modeling

Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches

Use of the informational spectrum methodology for rapid biological analysis of the novel coronavirus 2019-nCoV: prediction of potential receptor, natural reservoir, tropism and therapeutic/vaccine target

Designing inhibitors for the SARS CoV main protease as anti-SARS drugs

High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase

Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection

The spike protein of SARS-CoV -A target for vaccine and therapeutic development

Tilorone: A Broad-Spectrum Antiviral Invented in the USA and Commercialized in Russia and Beyond

The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus

Structure-based stabilization of non-native protein-protein interactions of coronavirus nucleocapsid proteins in antiviral drug design

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

HIV protease inhibitor nelfinavir inhibits replication of SARS-associated coronavirus

The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: Implications for the development of vaccines and antiviral agents

Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio

Discovery and development of safe-in-man broad-spectrum antiviral agents

Antivirals in medical biodefense

Efficacies of lopinavir/ritonavir and abidol in the treatment of novel coronavirus pneumonia

Chloroquine for the 2019 novel coronavirus

Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia

A combination regimen by lopinave/litonawe (LPV/r), emtricitabine and tenofovir alafenamide fumarate (FTC/TAF) for treatment of novel coronavirus pneumonia (TARCoV)

Nucleotide Analogues as Inhibitors of Viral Polymerases

A Short Note on Potential 2019-ncov Treatment

Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China

Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting

Drug treatment options for the 2019-new coronavirus (2019-nCoV). Biosci Trends

Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia

Severe 2019-nCoV Remdesivir RCT

Mild/Moderate 2019-nCoV Remdesivir RCT

Glucocorticoid Therapy for Novel CoronavirusCritically Ill Patients With Severe Acute Respiratory Failure

A Randomized Multicenter Controlled Clinical Trial of Arbidol in Patients With

Efficacy and Safety of Hydroxychloroquine for Treatment of Pneumonia Caused by 2019-nCoV ( HC-nCoV )

Efficacy and Safety of Darunavir and Cobicistat for Treatment of Pneumonia Caused by 2019-nCoV

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia

Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia

The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection

Is lithium a potential treatment for the novel Wuhan (2019-nCoV) coronavirus? A scoping review

Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury

On the use of corticosteroids for 2019-nCoV pneumonia. The Lancet

Inhibitors of RAS Might Be a Good Choice for the Therapy of COVID-19 Pneumonia

Broad-spectrum coronavirus antiviral drug discovery

Clinical Efficacy of Arbidol in Patients with 2019 Novel Coronavirus-Infected Pneumonia: A Retrospective Cohort Study

Teicoplanin potently blocks the cell entry of 2019-nCoV

Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia

Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia

Sofosbuvir Can Inhibit the Newly Emerged Coronavirus (2019-nCoV) in Wuhan

Network-based Drug Repurposing for Human Coronavirus

Pharmacoinformatics and Molecular Dynamic Simulation Studies Reveal Potential Inhibitors of SARS-CoV-2 Main Protease 3CLpro

Potential inhibitors against papain-like protease of novel coronavirus (COVID-19) from FDA approved drugs

Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model

Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking

Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates

Virtual screening of an FDA approved drugs database on two COVID-19 coronavirus proteins

Anti-HCV, nucleotide inhibitors, repurposing against COVID-19

Anti-SARS and Anti-HCV Drugs Repurposing Against the Papain-like Protease of the Newly Emerged Coronavirus (2019-nCoV)

Potential Candidate to Repurpose for Coronavirus Infection: Virtual Screening and Molecular Docking Study

Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19. bioRxiv

Targeting Novel Coronavirus 2019: A Systematic Drug Repurposing Approach to Identify Promising Inhibitors Against 3C-like Proteinase and 2'-O-Ribose Methyltransferase

Therapeutic Drugs Targeting 2019-nCoV Main Protease by High-Throughput Screening. bioRxiv

Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases. bioRxiv

Potentially highly potent drugs for 2019-nCoV

Machine intelligence design of 2019-nCoV drugs

Repurposing Therapeutics for the Wuhan Coronavirus nCov-2019: Supercomputer-Based Docking to the Viral S Protein and Human ACE2 Interface

Virtual High Throughput Screening Based Prediction of Potential Drugs for COVID-19

Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds

Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) Through Computational Drug Repurposing Study

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

Nelfinavir was predicted to be a potential inhibitor of 2019-nCov main protease by an integrative approach combining homology modelling, molecular docking and binding free energy calculation

How to Live Better, Longer

Molecular dynamics simulations and novel drug discovery

The papain-like protease determines a virulence trait that varies among members of the SARScoronavirus species

Multi-target pharmacology: possibilities and limitations of the "skeleton key approach" from a medicinal chemist perspective

Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug discovery today

Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annual review of pharmacology and toxicology

Atazanavir inhibits SARS-CoV-2 replication and pro-inflammatory cytokine production

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19

Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro

Lack of Antiviral Activity of Darunavir against SARS-CoV-2

Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future

Preliminary Recommendations for Lung Surgery during 2019 Novel Coronavirus Disease (COVID-19) Epidemic Period

2019-nCoV (Wuhan virus), a novel Coronavirus: human-to-human transmission, travel-related cases, and vaccine readiness

Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province

Not applicable

☒ The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.☐The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: